BUND FINANCE

BUND FINANCE › Stocks › BMY

Bristol-Myers Squibb Company (BMY)

NYSE · Stock price, chart and technical analysis

US$59.56-1.79 (-2.92%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$61.35
OpenUS$60.78
Day rangeUS$59.48 – US$61.16
52-week rangeUS$45.27 – US$68.64
Market capUS$121.75B
Volume9.54M
50-day averageUS$61.75
200-day averageUS$60.41
Beta0.23
Last dividend per shareUS$2.52

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$46.4BUS$46.2BUS$45.0BUS$48.3BUS$48.2B
Net incomeUS$7.0BUS$6.3BUS$8.0B−US$8.9BUS$7.1B
EPS (diluted)3.122.953.86-4.413.45
Gross margin78.6%78.0%76.2%71.1%71.1%
Operating margin18.4%19.7%18.2%12.2%28.5%
Net margin15.1%13.7%17.8%-18.5%14.6%
Free cash flowUS$15.2BUS$11.9BUS$12.7BUS$13.9BUS$12.8B
Total debtUS$45.6BUS$40.7BUS$41.5BUS$51.2BUS$47.1B
CashUS$14.0BUS$9.1BUS$11.5BUS$10.3BUS$10.2B

Compound annual growth: revenue 1.0% · net income 0.2% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E13.2x18.2x27.1x
EV / EBITDA10.2x16.8x16.5x
Operating margin26.1%—3.6%
Net margin18.5%—-0.0%
Debt / equity2.79—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Bristol-Myers Squibb Company

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
CEOChristopher Boerner
Employees32,500
IPO date1972-06-01

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also fe…

www.bms.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice